Loading...
Please wait, while we are loading the content...
Similar Documents
Pmh11 Medication Use Patterns and Costs Associated with Atypical Antipsychotics in the Treatment of Bipolar Disorder
| Content Provider | Semantic Scholar |
|---|---|
| Author | Zhu, Baojin Kulkarni, Pandurang M. Stensland, Michael D. Ascher-Svanum, Haya |
| Copyright Year | 2007 |
| Abstract | effects associated with VPA and DVPX-ER estimated by the expert panel was 0.36 and 0.10 respectively. The average probability of treatment success for VPA and DVPX-ER was estimated to be 0.45 and 0.58 respectively. In the base case analysis, the expected total cost per patient was $33,525 and $24,968 for VPA and DVPX-ER respectively, a difference of $8557 favoring ER. The expert panel also estimated the frequency of drug switching within one year for VPA and DVPX-ER to be 58.3% and 28.7% for VPA and DVPX-ER respectively. Finally, sensitivity analysis results indicated DVPX-ER was the preferred option when the probability of disease control with VPA was 0.5 or less, across all GI event probabilities with VPA. CONCLUSION: The results from our decision analysis, based on probabilities of major events and associated utilization from an expert panel, suggest that divalproex sodium extended-release provides greater net benefit than valproic acid in the treatment of bipolar disorder. |
| File Format | PDF HTM / HTML |
| DOI | 10.1016/S1098-3015(10)68764-5 |
| Volume Number | 10 |
| Alternate Webpage(s) | https://core.ac.uk/download/pdf/82589345.pdf |
| Alternate Webpage(s) | https://doi.org/10.1016/S1098-3015%2810%2968764-5 |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |
